01—Abstract
Summary
Summary of the 8-K filed May 12, 2026. Cited figures are marked; the original filing is the authoritative source.
Oracle Corporation (NYSE: ORCL) filed a Form 8-K on May 12, 2026 to disclose the election of Dr. Tomislav Mihaljevic to its Board of Directors.
The Board unanimously elected him effective May 6, 2026, and increased the Board's size from 12 to 13 seats. Dr. Mihaljevic is CEO and President of Cleveland Clinic, a position he has held since January 2018, and previously served as a director of GE HealthCare. He has not been assigned to any Board committee at this time.
The filing is a routine corporate governance event with no disclosed financial impact. Oracle does not report any material operating, financial, or legal developments in this 8-K. Dr. Mihaljevic will receive a standard annual grant of restricted stock units under Oracle's 1993 Directors' Stock Plan, scheduled for May 31, 2026, which fully vests after one year of continued board service.
He will also receive standard non-employee director cash compensation and Oracle's standard indemnification agreement. The filing states he has no related-party transactions requiring disclosure and no family relationships with Oracle's directors or executives. For investors, the appointment is mainly notable for adding healthcare executive experience to the Board, which management links to Oracle's push to provide cloud and technology solutions to healthcare organizations.
The Press release also notes that directors serve one-year terms and will next stand for election at the November 2026 annual meeting. Investors should view this as a low-impact governance update rather than a signal of strategic or financial change.
02—Key points
Key Highlights
- Tomislav Mihaljevic, CEO and President of Cleveland Clinic, was elected to Oracle's Board effective May 6, 2026.
- The Board was expanded to 13 members with this appointment.
- Dr. Mihaljevic has not been named to any Board committee and none is currently expected.
- He will receive a standard annual RSU grant on May 31, 2026, vesting fully on the one-year anniversary, plus standard non-employee director cash compensation.
- Oracle will provide him its standard director indemnification agreement; no related-party transactions or family relationships were reported.
- Mihaljevic previously served as CEO of Cleveland Clinic Abu Dhabi (2015-2017) and as a director of GE HealthCare.
- The filing reports no material financial impact; the announcement is a Regulation FD disclosure furnished under Exhibit 99.1.
03—Questions
Frequently Asked Questions
Who is the new Oracle director and what is his background?
Dr. Tomislav Mihaljevic is CEO and President of Cleveland Clinic, a role he has held since January 2018. He served as CEO of Cleveland Clinic Abu Dhabi from 2015 to 2017, previously was Chief of Staff and Chairman of the Heart & Vascular Institute there, and joined Cleveland Clinic as a surgeon in 2004. He also previously served as a director of GE HealthCare.
Will Dr. Mihaljevic serve on any Board committees?
Not at this time. The filing states he has not been named to any committee and is not currently expected to be named to one.
How is Dr. Mihaljevic compensated?
He will receive restricted stock units under Oracle's Amended and Restated 1993 Directors' Stock Plan on May 31, 2026, consistent with the annual award for non-employee directors. The RSUs fully vest on the first anniversary of grant if he remains a director. He will also receive the standard cash compensation for non-employee directors.
Does this appointment affect Oracle's financial results or strategy?
The filing does not disclose any financial impact or strategic change. Management's comments frame the appointment as adding healthcare and risk management expertise to help Oracle serve healthcare customers with its technology.
When will the Board seat be up for election again?
Directors serve one-year terms, and Dr. Mihaljevic will next stand for election at Oracle's annual stockholder meeting in November 2026.
04—Continue